We offer security of supply by:
We deliver on our promises to customers by:
Continuity is the core of our strategy. Although we have grown and innovated significantly over the course of our history, we have always done this gradually with limited risks and with close attention to all the people involved.
Most of our products are well established. Our extensive experience has enabled us to optimize processes for quality and efficiency.
Most of the equipment in our plant is multi-purpose. Many multi-step processes are executed in separate campaigns with stock of intermediates. This arrangement allows for extra flexibility and supply security compared to dedicated and integrated production lines, which are more common in the production of Active Pharmaceutical Ingredients.
Because our organisation is small and agile, we can adjust planning and execute projects for changes in processes and equipment relatively quickly, without compromising on quality or HSE requirements.
When qualifying suppliers of critical raw materials, we focus on their quality system and the potential impact on the quality of our products. However, we also evaluate how suppliers perform in Health, Safety and Environment and we assess business continuity risks. Our approach is to evaluate risks across the supply chain.
The COVID-19 pandemic and tariffs seem to have led to a push for more domestic production of pharmaceuticals and Active Pharmaceutical Ingredients, especially in the United States and Europe. There seems to be more concern about dependence on imports from India and China in particular.
We welcome this discussion. We also welcome the recognition of API manufacturers contributing substantially to society. However, in order to actually improve the security of supply of pharmaceuticals and APIs, we do not believe in the mantra “buy domestically”. We believe in a tailored approach, assessing risks per product across the supply chain. In our view the assessment should be about the number of suppliers in each step of the supply chain, including early stage chemical intermediates, and the supply risk profiles of those specific manufacturers. The assessment should not only look at whether pharmaceuticals and APIs are imported or manufactured domestically.
We believe that regulators and payors for pharmaceuticals as well as pharma companies need to strike a good balance between cost and risks. It is often not feasible to drive down costs without compromising on risks for supply security and quality. Environmental impacts and conditions for factory workers should also be considered when making sourcing decisions.
Katwijk Chemie is confident that it can offer an attractive package to customers, security of supply at competitive prices, while also thinking about the impact of our operations on people and the environment.
